Yes. A PSEN2 genetic test can change dementia care decisions during a second opinion for suspected early-onset familial Alzheimer disease.
A positive result can confirm the diagnosis and shift care, family planning, and trial options. PSEN2 is a gene linked to early-onset familial Alzheimer disease. Variants are passed in an autosomal-dominant pattern, so a child of a carrier has a 50% chance of inheriting the variant, according to MedlinePlus Genetics.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does a positive result settle?
- How does it change decisions for relatives?
- Who is most likely to benefit?
- What should happen before and after testing?
What does a positive result settle?
A second opinion often focuses on whether symptoms reflect familial early-onset disease. Detecting a mutation in APP, PSEN1, or PSEN2 confirms the diagnosis in a person with suspected familial early-onset dementia, according to a clinical-utility review in Neurology International. That clarity can end repeated testing and direct care toward Alzheimer-specific planning.
Confirmation also helps specialists tailor support. Families can move from possible causes to practical choices about supervision, work changes, driving, advance directives, and long-term care. Experts advise referral to a familial-dementia clinician when this pattern is suspected.
How does it change decisions for relatives?
A positive PSEN2 result identifies at-risk relatives who may need screening, monitoring, or predictive testing. It can guide reproductive decisions, long-term financial and care planning, and offers of predictive testing to relatives, according to joint ACMG and NSGC guidelines.
For adult children and siblings, the result makes risk concrete rather than general. Some relatives will pursue predictive testing, while others will use the information for timing of career, housing, insurance, and family decisions. Counseling helps each person choose without pressure.
Who is most likely to benefit?
PSEN2 mutations are rare, explaining only about 1–2% of all Alzheimer cases. Testing is most useful with early onset or strong autosomal-dominant family history, where cases appear in successive generations.
A useful second-opinion question is whether the family pattern fits. Early symptoms in a parent, aunt, uncle, or sibling, especially before age 65, raise the value of review. Without that pattern, routine PSEN2 testing rarely changes care.
What should happen before and after testing?
Guidelines call for pre- and post-test counseling, baseline neurologic examination, informed consent with a family member present, and generally avoiding testing minors. Bring medical records, symptom timelines, medication lists, and a three-generation family history to the second opinion. People with PSEN1, PSEN2, or APP mutations or at-risk family members can join Dominantly Inherited Alzheimer Network observational and prevention trials unavailable to sporadic cases.
- Ask whether familial early-onset Alzheimer disease is suspected
- Ask about referral to a familial-dementia clinic and genetic counselor
- Clarify how results would affect diagnosis, care, relatives, and trial eligibility
- Plan follow-up for disclosure, support, and predictive-testing offers
